Skip to content
Baltimore News Journal – Lifestyle
Author:
Aptevo Therapeutics
Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant
October 26, 2026
Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting
October 14, 2026
Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
September 24, 2026
Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML
September 3, 2026
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results
August 14, 2026
Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds
August 13, 2026
Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds
August 12, 2026
Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone
July 27, 2026
Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors
June 30, 2026
Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer
May 28, 2026
1
2
Next Page
→